Trial Profile
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs T-cell vaccine-TVAX Biomedical (Primary) ; Interleukin-2
- Indications Glioma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors TVAX Biomedical
- 25 Jun 2014 New trial record
- 26 Aug 2010 According to CT.gov record, status changed from recruiting to active, no longer recruiting.
- 12 Apr 2010 According to CT.gov record, status changed from not yet recruiting to recruiting.